ORLANDO, FLORIDA—Patients receiving radiotherapy for high-risk node-negative prostate cancer benefit as much from 18 months of androgen blockade as from the usual 36 months but have fewer side effects — according to study findings announced at the 2013 ASCO Genitourinary Cancers Symposium in Orlando by Dr Abdenour Nabid from Sherbrooke University in Quebec.
You may also like...
International Research and Consensus Needed to Interpret Breast Cancer Genomics Data 27 Mar, 2015 Audio Journal of Oncology in Advance – January 15th, 2007 – HERA Study Results Confirm Trastuzumab Benefit in HER2 Positive Early Breast Cancer 17 Jan, 2007 Chronic Myeloid Leukemia ‘To Become A Very Indolent Disease’: Pregnancy Possible, Transplants Avoided—Mission Accomplished? 21 Apr, 2009 ASCO Audio Journal of Oncology in Advance – February 15th, 2007 – reporting from San Antonio Breast Cancer Symposium, December 13-17, 2007 16 Feb, 2007
- Previous story MDFM News: Overview of the 2nd World Summit on Gut Microbiota (section of the European Society of Neurogastroenterology and Motility)
- Next story Low risk prostate cancer: less treatment means lower cost, and better patient outcomes
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014